Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Next revision		Previous revision
pd [2023/07/03 09:34] – created - external edit 127.0.0.1pd [2024/04/06 15:50] (current) – [Parkinson's Disease] sflitman
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator  ^  Duration  ^  Open Label Extension  ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator  ^  Duration  ^  Open Label Extension  ^
-| New Onset Parkinson's Disease | Novel Oral Dopamine Agonist |  III  |  No   |  Placebo |  24 weeks  |  9 months  | +| Parkinson's Disease | Novel oral D1PAM |  III  |  No   |  Placebo  |  24 weeks  |  9 months  | 
-| Mild to Moderate Parkinson's Disease | Novel Oral Dopamine Agonist  |  III  |  Yes   |  Placebo  |  24 weeks  |  9 months  | + 
-| Moderate to Advanced Parkinson's Disease | Carbidopa/Levodopa Continuous Subdermal infusion |  III  |  Yes  |  Sham infusion  | 12 months  |  Yes  | +
-| Dyskinesias in Parkinson's Disease | Novel oral agent |  II  |  Yes  |  50%  |  12 weeks  |  No  | +
-| Dyskinesias in Parkinson's Disease | Novel oral agent |  II  |  Yes  |  33%  |  1 year  |  No  |+
  
-<html><!-- 
-| Moderate to Severe Parkinson's Disease | Oral adenosine-2a antagonist |  III  |  Yes  |  33%  |  12 weeks  |  Yes  | 
---></html> 
  
 ====== Response Form ====== ====== Response Form ======

Trace:

Print/export
QR Code
QR Code pd (generated for current page)